UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Market Authorisation to Marksans Pharma’s wholly owned subsidiary Relonchem for Fluoxetine 20mg/5ml Oral Solution.
Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders. The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.